Table 1 Sample characteristics: descriptive analysis according to microorganism group
Patient’s characteristics | K. pneumoniae (n = 337) | E. cloacae (n = 77) | K. aerogenes (n = 29) |
|---|---|---|---|
Sex | |||
 Female | 134 (39.8%) | 24 (31.2%) | 8 (27.6%) |
 Missing | 2 (0.6%) | 0 (0.0%) | 0 (0.0%) |
Age* | |||
 18–59 | 79 (23.4%) | 23 (29.9%) | 3 (10.3%) |
 60–69 | 93 (27.6%) | 20 (26.0%) | 9 (31.0%) |
 70–79 | 91 (27.0%) | 21 (27.3%) | 11 (37.9%) |
 ≥ 80 | 74 (22.0%) | 13 (16.9%) | 6 (20.7%) |
Charlson index* | |||
 ≥ 5 | 159 (47.2%) | 34 (44.2%) | 15 (51.7%) |
Department responsible | |||
 Medical | 185 (54.9%) | 38 (49.4%) | 19 (65.5%) |
 Surgery | 73 (21.7%) | 22 (28.6%) | 5 (17.2%) |
 ICU | 42 (12.5%) | 10 (13.0%) | 3 (10.3%) |
 Other | 29 (8.6%) | 5 (6.5%) | 2 (6.9%) |
 Missing | 8 (2.4%) | 2 (2.6%) | 0 (0.0%) |
Setting of BSI acquisition* | |||
 Community | 90 (26.7%) | 8 (10.4%) | 9 (31.0%) |
 Nosocomial | 155 (46.0%) | 55 (71.4%) | 12 (41.4%) |
 HAI | 92 (27.3%) | 14 (18.2%) | 8 (27.6%) |
BSI source | |||
 Abdominal | 79 (23.4%) | 21 (27.3%) | 6 (20.7%) |
 Catheter | 33 (9.8%) | 14 (18.2%) | 3 (10.3%) |
 Respiratory | 21 (6.2%) | 4 (5.2%) | 3 (10.3%) |
 Urinary | 141 (41.8%) | 14 (18.2%) | 11 (37.9%) |
 Other | 8 (2.4%) | 3 (3.9%) | 0 (0.0%) |
 Unknown | 54 (16.0%) | 21 (27.3%) | 6 (20.7%) |
 Missing | 1 (0.3%) | 0 (0.0%) | 0 (0.0%) |
Pitt score* | |||
 ≥ 4 | 35 (10.4%) | 7 (9.1%) | 2 (6.9%) |
Severe sepsis* | |||
 Yes | 66 (19.6%) | 11 (14.3%) | 5 (17.2%) |
Septic shock* | |||
 Yes | 51 (15.1%) | 7 (9.1%) | 5 (17.2%) |
ESBL production | |||
 Yes | 79 (23.4%) | 2 (2.6%) | 0 (0.0%) |
 Missing | 85 (25.2%) | 23 (29.9%) | 9 (31.0%) |
Carbapenemase production | |||
 Yes | 33 (9.8%) | 0 (0.0%) | 1 (3.4%) |
 Missing | 110 (32.6%) | 27 (35.1%) | 10 (34.5%) |
Active empiric antibiotic | |||
 Yes | 250 (74.2%) | 47 (61.0%) | 19 (65.5%) |
 Missing | 41 (12.2%) | 14 (18.2%) | 2 (6.9%) |
Time to start ATB | |||
 Before | 59 (17.5%) | 10 (13.0%) | 3 (10.3%) |
 Same day | 199 (59.1%) | 47 (61.0%) | 18 (62.1%) |
 ≥ 1 days after | 43 (12.8%) | 9 (11.7%) | 5 (17.2%) |
 Missing | 36 (10.7%) | 11 (14.3%) | 3 (10.3%) |
Composite outcome* | 64 (19.0%) | 16 (20.8%) | 2 (6.9%) |
Recurrence* | 15 (4.5%) | 8 (10.4%) | 0 (0.0%) |
All-cause mortality* | 62 (18.4%) | 15 (19.5%) | 2 (6.9%) |
Infection related mortality* | 38 (11.3%) | 7 (9.1%) | 1 (3.4%) |
Persistent BSI* | 19 (5.6%) | 5 (6.5%) | 0 (0.0%) |
Fever ≥ 72H* | 49 (14.5%) | 11 (14.3%) | 5 (17.2%) |
Device infection* | 8 (2.4%) | 1 (1.3%) | 1 (3.4%) |
Length of hospital stay | 14 (7, 31) (n = 239) | 21 (11, 35) (n = 54) | 11 (4, 22) (n = 19) |
Follow-up time, days | 31 (11, 73) (n = 337) | 26 (11, 52) (n = 77) | 30 (11, 61) (n = 29) |